Table 5.
First analysis | Second analysis | |||||
Odds ratio | 95% CI | p Value | Odds ratio | 95% CI | p Value | |
Menopausal status | 1.63 | 0.44 to 6.05 | 0.467 | 1.89 | 0.55 to 6.51 | 0.312 |
Tumour size | 1.75 | 0.46 to 6.68 | 0.411 | 1.80 | 0.51 to 6.40 | 0.363 |
Clinical nodal status | 5.48 | 1.24 to 24.16 | 0.025 | 5.44 | 1.35 to 21.87 | 0.017 |
Grade | 0.21 | 0.03 to 1.33 | 0.098 | 0.16 | 0.03 to 0.91 | 0.039 |
Clinical response after two cycles | 3.68 | 0.90 to 15.03 | 0.069 | - | - | - |
Hormonal receptor | 27.00 | 2.21 to 330.57 | 0.010 | 7.83 | 1.24 to 49.42 | 0.029 |
Ki-67 | 0.75 | 0.16 to 3.56 | 0.716 | 0.78 | 0.18 to 3.39 | 0.740 |
HER2 | 4.09 | 0.70 to 24.08 | 0.119 | 3.66 | 0.69 to 19.30 | 0.126 |
p53 | 4.11 | 0.73 to 23.01 | 0.108 | 2.55 | 0.56 to 11.66 | 0.227 |
bcl-2 | 3.75 | 0.35 to 39.54 | 0.272 | 4.98 | 0.53 to 46.95 | 0.161 |
HER2, human epidermal growth factor receptor 2.